AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations

Abstract

AT-101 enhances gefitinib sensitivity in NSCLC with EGFR T790M mutations. The addition of AT-101 to gefitinib is a promising strategy to overcome EGFR TKIs resistance in NSCLC with EGFR T790M mutations.